S_nmary The monoclonal antibody (MAb) A7 has been used to treat patients with colorectal or pancreatic carcinoma with encouraging results. We therefore determined if MAb A7 would also react with gastric carcinoma cell lines. MAb A7 reacted with seven of eight gastric carcinoma cell lines tested. The intensity of the reaction, measured by flow cytometry, was equal to that of WiDr (colon) and HPC-YS (pancreas) cell lines. In nude mice bearing xenografts of the MAb A7-reactive gastric cancer line MKN45, the percentage injected dose of MAb A7 per g of tumour tissue on day 7 was 9.79; this value was 77% of that on day 1. The in vivo tumour-to-blood ratio of MAb A7 was 2.77 on day 7. Therefore, MAb A7 has long-term retention at binding sites as well as a high probability, high intensity and high specificity of reactivity against gastric cancer, which make it an ideal drug carrier for immunotargeted chemotherapy and immunodiagnosis. 
Many gastric cancers are now detected at an early stage, mainly because of mass screening and recent improvements in gastrofibrescopic endoscopy. Early gastric cancers now account for almost 50% of clinically detected gastric cancers in Japan (Bollschweiler et al., 1993) and 95% of patients with early gastric cancer can be cured by surgery (Inoue et al., 1991; Moriguchi et al., 1991) . Gastric cancer remains the most common carcinoma in Japan (Tominaga, 1987) . Thus, there are still many advanced cases of gastric cancer that lead to death despite surgical treatment and chemotherapy. Ultrasound tomography, computerised tomography (CT) and angiography are routinely used in the staging of gastric cancer. But their sensitivity and specificity limit their ability in preoperative staging and evaluating the completeness of a resection.
One possible approach to overcome the limitations of both current chemotherapy and present diagnostic techniques is to attach anti-cancer agents or radionuclei to monoclonal antibodies (MAbs) against various solid tumours, so that a drug or radioactive isotope can be selectively confined to tumour cells (Tjandra et al., 1989; Boeckmann et al., 1990; Elias et al., 1990; Jan-Erik et al., 1990; Hani et al., 1991) . We have developed MAb A7 against a human colonic carcinoma (Kotanagi et al., 1986) and have covalently combined MAb A7 with the anticancer antibiotic neocarzmnostatin (NCS) to produce a MAb-drug conjugate, A7-NCS. A7-NCS has a significant anti-tumour effect on grafted human colonic carcinoma in nude mice. We have already treated patients with colorectal carcinoma with A7-NCS and have obtained encouraging results. An early A7-NCS trial has shown that three of eight patients with post-operative liver metastasis showed evidence of tumour reduction on CT scan, and three obtained pain relief without severe adverse effects (Takahashi et al., 1988) . Furthermore, A7-NCS treatment prolonged survival time when compared with conventional chemotherapy in the patients with liver metastasis (median survival times: A7-NCS group, 328 days; conventional chemotherapy group, 128 days; P<0.05) (Takahashi et al., 1993) . Furthermore, in our recent study, MAb A7 was shown to react with 77% of human pancreatic carcinoma cell lines as well as with human colonic carcinoma (Otsuji et al., 1990 (Yamaguchi et al., 1990 ).
All the cell lines were maintained in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Flow Laboratories, Rockville, MD, USA).
Monoclonal antibodies
The murine monoclonal antibody MAb A7 was developed against huan colonic carcinoma as described previously (Kotanagi et al., 1986) . MAb A7 has been shown to react with a 45 kDa surface glycoprotein of human colonic carcinomas (Kitamura et al., 1989) and 77% of the human pancreatic carcinoma cell lines tested, including HPC-YS. The A7 antigen loses antigenic activity after sodium periodate, pronase and ficin treatments. MAb A7 does not react with normal gastric mucosa, erythrocytes, peripheral lymphocytes or ileal mucosa, and has weak reactivity with 10% of colon mucosa specimens (Kotanagi et al., 1986 Figure 2 , the cell surface of MKN45 and KATO III was stained with MAb A7 FITC immunofluorescence staining and a cell nucleus was dyed with PI. By contrast, in the case of MKNI, the cell surface was not stained, only a cell nucleus was dyed by PI. In vivo distribution of radiolabelled antibodies More radiolabelled MAb A7 accumulated in the grafted MKN45 tumours than in the blood after day 3, and high radioactivity was maintained until day 7 (Figure 3 ). On the other hand, less radiolabelled normal mouse IgG accumulated in the tumour than in the blood at all times. In contrast, in mice harbouring MKN1 both radiolabelled IgG and MAb A7 localised less in the tumour than in the blood at all points of study ( Figure 4 ).
Preparation of radiolabelled MAbs
MAb A7 and normal mouse IgG labelled with "2I (IMS 30, Amersham Japan) were obtained by the chloramine-T method (Hunter & Greenwood, 1962 To compare the specific localisation of MAb A7 in the tumour with that in the normal tissues, the ratio of radioactivity in these tissues to that in the blood was calculated. These ratios were derived by dividing the radioactivity in the various tissues on a per weight basis by that in the total blood on a per weight basis. The Student's t-test was used to check for statistically significant differences. A P-value of less than 0.05 was considered to be statistically significant.
The distribution of the antibodies in the tumours was also measured by the same method using nude mice harbouring MKN1 tumours. Figure 3 . Symbols as in Figure 3 .
The MAb A7 tumour-to-blood ratio rose progressively to 2.77 ± 0.19 on day 7 ( Figure 5 ). In contrast, the values in normal organs were all below 0.38 ± 0.09 and did not change over time. The normal mouse IgG tumour-to-blood ratio ranged from 0.25 ± 0.07 to 0.32 ± 0.06 during this experiment. The difference in tumour-blood ratio between the two groups was statistically significant. Histological heterogeneity is a characteristic feature of gastric cancer that differs from colorectal cancer. In this report, we studied the reactivity of MAb A7 with various histological types of cancer cell lines. MAb A7 reacted with the common types of gastric cancer cells regardless of the degree of differentiation, but it did not react with the adenosquamous carcinoma cell line, MKN1. It has been previously reported that MAb A7 does not react with a squamous cell carcinoma cell line, KB-2 (Otsuji et al., 1992) . However, the common types are the absolute majority of all gastric carcinomas. Therefore, MAb A7 has a high probability of reacting with gastric carcinoma.
According to our flow cytometry measurements, the in vitro intensity of the reactivity with the common types of gastnc carcinoma cell lines was as high as that with the colonic carcinoma cell line WiDr and the pancreatic carcinoma cell line HPC-YS. Moreover, the in vivo percentage injected dose per g of tumour tissue of MAb A7 to MKN45 on day 7 was 9.79. Those of the colonic carcinoma cell line Colon 6 and the pancreatic carcinoma cell line HPC-YS on day 8 were 8.18 and 3.3 respectively (Takahashi, 1985; Otsuji et al., 1992) . These findings indicate that MAb A7 has a high intensity of reactivity with gastric carcinoma, similar to its reactivity with colonic and pancreatic carcinoma.
The in vivo tumour-to-blood ratio of MAb A7 is a good index of the specificity of MAb A7. The tumour-to-blood ratio of MKN45 on day 7 was 2.77, 8.65 times that of normal mouse IgG. The ratio in the colonic carcinoma cell line Colon 6 was 2.38 on day 8 and was 2.04 in the pancreatic carcinoma cell line HPC-YS (Takahashi, 1985 ; Otsuji et al., 1992) . The tissue-to-blood ratio of each of the normal organs was significantly lower than the tumour-to-blood ratio, and no difference between MAb A7 and normal mouse IgG was found. These findings indicate that MAb A7 has a high specificity for gastric carcinoma, similar to that for colonic and pancreatic carcinomas. Reintgen et al. (1983) have reported that an antibody tumour-blood ratio must be greater than 2-10 for reliable tumour imaging, and Tsuda et al. (1990) have successfully performed immunoscintigraphy of tumour xenografts in nude mice after injection of an '3'I-labelled MAb. which achieves a tumour tissue-blood ratio of 3.1. Moreover, the low distribution of A7 to normal organs may lead to a low incidence of side-effects during therapy and low background during diagnostic scintigraphy.
The in vivo percentage injected dose of MAb A7 per g of tumour tissue on day 7 was 77% of that on day 1. This shows that MAb A7 is retained at the binding sites, and means that the dose of the anti-tumour agent which is carried out by MAb A7 could be decreased, and would not have to be administered frequently, which may also reduce the incidence of side-effects.
Recently, Sickle-Santanello et al. (1987) have developed a hand-held gamma detection probe for intraoperative use. The aim of radical surgery for gastric cancer is to provide an uninvolved surgical margin and lymph nodes. However, in practice, tissues dissected during this procedure may not be involved pathologically. A radioimmuno-guided procedure using MAbs may be useful for determining the extent of a gastric cancer.
In conclusion, MAb A7 has the characteristics of an ideal drug carrier for immunotargeted chemotherapy and radiolabelled monoclonal antibody imaging of gastric cancer. We expect that MAb A7 will prove clinically useful for the treatment of gastric carcinoma.
